

**ASH VTE GUIDELINES FOR LATIN AMERICA
ADOLOPMENT Project – Expert-Based Evidence Form**

**Background**

This form is used to gather information to be included in the Evidence to Decision Frameworks. In this specific project, we are interested in obtaining information about resource use, cost-effectiveness, impact on health equity, accessibility and feasibility.

We really appreciate your input.

We are interested on the following interventions:

***Drugs and devices:***

1. Unfractioned heparin
2. Low molecular weight heparins
3. Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban)
4. Aspirin
5. Thrombolytics
6. Compression stockings
7. Pneumatic compression devices
8. 4-factor Prothrombin Complex Concentrate (PCC)
9. Fresh Frozen Plasma

***Laboratory test:***

1. D-dimer test

***Other:***

1. Hospital admission due to VTE
2. Anticoagulation clinics for management of patients on anticoagulants

**Please write your name:**

**To which country or countries is relevant the information you are providing?**

**Section A: Resource Use and Cost-effectiveness**

The costs and resource use is one of the factors considered in formulating recommendations. Guideline panels must evaluate the potential costs, resource use, and consequent impact on the healthcare system and determine whether the costs are large or small relative to the net benefits of the interventions.

1. From your knowledge, is there any study, information or data about the resource consumption of the previous interventions in your country? (including economic evaluations, cost-effectiveness studies, and total cost of the interventions)

1. **Section B: Impact on health equity**

The potential impact in health equity is another of the factors considered in formulating recommendations. Guideline panels must evaluate whether there are potential groups or settings that might be disadvantaged in relation to the relevant interventions. Also, whether there are important considerations that should be made when implementing the interventions in order to ensure that inequities are reduced, if possible.

1. From your knowledge, is there any study, information or data about potential groups or settings that might be disadvantaged in relation to the relevant interventions?

1. Is there any important consideration that should be made when implementing the relevant interventions in order to reduce health inequities?

**Section C: Acceptability**

The acceptability of interventions from key stakeholder is also considered in formulating recommendations. Guideline panels must evaluate whether key stakeholders would accept or disapprove the interventions or the potential benefits, harms and costs related with the interventions.

1. From your knowledge, is there any study, information or data about acceptability of the relevant interventions in your country?

**Section D: Feasibility**

Finally, feasibility of interventions is considered in formulating recommendations. Guideline panels must evaluate whether interventions are sustainable and whether there are important barriers that likely will limit the implementation.

1. From your knowledge, is there any study, information or data about potential barriers that likely will limit the implementation of the relevant interventions in your country?